Dose-dense weekly paclitaxel ( Taxol ) and carboplatin ( dd-TC ) improved survival compared with conventional tri-weekly paclitaxel and carboplatin ( c-TC ) as a first-line chemotherapy for newly diagnosed stage II-IV ovarian cancer in the Japanese Gynecologic Oncology Group 3016 trial .